Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) has shared an announcement.
Shareholders of Charmacy Pharmaceutical Co., Ltd. approved all resolutions at the annual general meeting held on 22 May 2026, including the 2025 board and auditor reports, the profit distribution plan and final dividend, director remuneration for 2026, and the reappointment of Pan-China Certified Public Accountants LLP. Investors also backed a plan for the company and its subsidiaries to obtain a comprehensive revolving credit line of up to RMB2.8 billion with related guarantees, and granted the board a general mandate to issue up to 20% of existing share capital, moves that enhance both financial flexibility and potential funding avenues for future expansion.
The resolutions were all passed by poll with overwhelming majorities, reflecting strong shareholder support for the company’s financial policies and governance structure. The new credit facilities and share issuance mandate are expected to provide Charmacy with additional tools to manage liquidity, pursue growth opportunities, and adjust its capital structure, which may influence its competitive stance in the pharmaceutical sector and affect returns for stakeholders over the coming year.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a PRC-incorporated pharmaceutical company listed in Hong Kong, operating in the healthcare sector with a focus on drug-related products and services. Its business centers on supplying pharmaceuticals in the Chinese market, positioning the group within the broader mainland healthcare and drug distribution industry.
Average Trading Volume: 1,500
Technical Sentiment Signal: Sell
Current Market Cap: HK$628.6M
See more data about 2289 stock on TipRanks’ Stock Analysis page.